Skip to main content
. 2020 Nov 7;12:168. doi: 10.1186/s13148-020-00961-y

Fig. 1.

Fig. 1

Decreased STXBP5-AS1 predicted poor prognosis in pancreatic cancer. a Kaplan–Meier’s analysis of the correlation between STXBP5-AS1 expression and the overall survival of PC patients. b Kaplan–Meier’s analysis of the correlation between STXBP5-AS1 expression and the relapse free survival of PC patients. c qRT-PCR analysis of STXBP5-AS1 expression in 60 pancreatic cancer tissues (PCT, 28 PC tissues from lymph node metastasis (LNM) patients and 32 PC tissues from lymph node metastasis-free (LNMF) patients) and respective adjacent normal tissues (ANT) (shown as 2−ΔΔCT). d, e STXBP5-AS1 expression in pancreatic tumor tissues and normal tissues from GSE16515 and GSE15471. f STXBP5-AS1 expression in six PC cell lines (AsPC-1, SW1990, Capan-2, CFPAC-1, PANC-1 and Mia PaCa-2) and a normal human pancreatic ductal cell line (hTERT-HPNE) was determined by qRT-PCR. g qRT-PCR analysis of STXBP5-AS1 expression in Gemcitabine-resistant (GR) or parental PANC-1 and Mia PaCa-2 cells. h The expression level of STXBP5-AS1 in spheres of PANC-1 and Mia PaCa-2 cells or parental PANC-1 and Mia PaCa-2 cells was measured by qRT-PCR.*P < 0.05; **P < 0.01